AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress ...Middle East

– Epcoritamab shows clinically meaningful efficacy in challenging-to-treat, highly refractory LBCL patients – Total patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 percent; CAR T-naïve patients achieved 69 percent ORR and 42 percent...

Hence then, the article about abbvie announces late breaking results from phase 2 trial of investigational epcoritamab duobody cd3xcd20 in patients with relapsed refractory large b cell lymphoma lbcl at the european hematology association eha annual congress was published today ( Saturday 11/06/2022 - 04:04 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress )

Also on site :

• List of all FIFA World Cup 2026 matches today & kick-off times (11 June)
• Windows of South Loop high rise shattered during severe storm
• UN watchdog demands Iran provide information on nuclear stockpile